Supernus initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Supernus (SUPN) with an Overweight rating and $57 price target Supernus has seven marketed products and three clinical-stage programs that target large opportunities in the central nervous system market including ADHD, Parkinson’s disease, epilepsy and depression, all with high unmet need, the analyst tells investors in a research note. The firm expects to hear a decision for SPN-830 in early 2025, with the company planning to launch in the first half of 2025, and believes Qelbree could be a growth driver for Supernus because it is a non-stimulant in the ADHD market, where 90% of the treatments are stimulants with potentially high abuse liability.